Uses of cannabis in dermatology

  There is promising evidence that cannabinoids (including THC, CBD, and related compounds like palmitoylethanolamide/PEA) can help relieve itching (pruritus), particularly chronic, neuropathic, refractory, or systemic forms. They are best positioned as adjuncts rather than first-line or standalone treatments for clearing rashes. Evidence comes from mechanistic studies, small clinical trials, case series, and recent systematic reviews/meta-analyses (including 2025 data), though high-quality large RCTs remain limited.

Where Cannabinoids May Fit in Itch Management

Cannabinoids appear more effective at reducing itch sensation than resolving underlying inflammatory rashes. Consider them as add-ons when standard therapies fall short:

• Core foundational care: Gentle skincare (fragrance-free moisturizers, lukewarm showers, soap-free cleansers, trigger avoidance), short courses of topical steroids or calcineurin inhibitors for eczema/dermatitis.
• Additional antipruritics: Menthol, pramoxine, phototherapy, or systemic agents (e.g., gabapentin, mirtazapine, antihistamines) based on itch type.
• Stronger signal conditions (low-to-moderate quality evidence):
  • Chronic pruritus (various causes).
  • Neuropathic itch (e.g., brachioradial pruritus, notalgia paresthetica).
  • Uremic pruritus (kidney disease) and cholestatic pruritus.
  • Atopic dermatitis and psoriasis: itch reduction with topicals; anti-inflammatory effects on rash are inconsistent.

Recent support: A 2024 double-blind RCT in hemodialysis patients showed a cannabis-containing cream (with CBD/THC) significantly reduced worst itch scores (from 6.7 to 2.6 at 4 weeks vs. 3.6 with placebo). A 2025 systematic review/meta-analysis confirmed a modest but statistically significant pruritus reduction overall.

Practical How-to-Use Guide

1. Start with Topicals (safest, most accessible option)
   • CBD cream/ointment (1–5%) or PEA-containing emollient, applied 1–2 times daily to affected areas for a 2–4 week trial.
   • Choose fragrance-free, third-party tested products (COA for purity/potency/contaminants). PEA (e.g., Levagen+) has shown good results in eczema-like symptoms.
   • Patch test: Apply a small amount to inner arm daily for 3 days.
   • Integrate into routine: Use after gentle cleansing with thick moisturizers. Avoid on broken, weeping, or infected skin.
   • Bonus: Some formulations combine with barrier-supporting lipids for added hydration.
2. Oral or Medical Cannabis (only under clinician supervision, off-label)
   • Reserve for severe, refractory generalized itch after other options.
   • Examples: Low-dose THC (nighttime), balanced THC:CBD, or prescription forms (nabilone, dronabinol) where available. Titrate slowly.
   • Avoid smoking/combustion due to unnecessary risks.
3. What Not to Expect
   • Do not use cannabinoids alone to clear inflammatory rashes (eczema, psoriasis flares). They complement, not replace, proven therapies.
   • Results vary; some patients see rapid relief, others modest or none.

Mechanism of Action

The skin has its own endocannabinoid system. Cannabinoids act on CB1/CB2 receptors on keratinocytes, immune cells, and nerves to dampen itch signals, reduce inflammation, and stabilize mast cells. They also interact with TRP channels (e.g., TRPV1) for desensitization and may reduce neurogenic inflammation. PEA works partly via similar pathways plus PPAR-α.

Safety, Side Effects, and Considerations

• Topicals: Generally well-tolerated. Possible irritation, allergic contact dermatitis (to terpenes or bases), or folliculitis from oily vehicles. Rare systemic absorption.
• Oral/THC: Drowsiness, dizziness, anxiety, dry mouth, cognitive effects, dependence risk. CBD may raise liver enzymes and interact with drugs (e.g., via CYP enzymes: warfarin, certain immunosuppressants, antidepressants).
• Contraindications: Pregnancy/breastfeeding, unstable psychiatric conditions, significant heart disease, or if operating machinery.
• Quality & Legal: Source from reputable brands. Legal status varies; medical programs offer more oversight. In the US (as of 2026), Schedule III changes may improve access/regulation for approved products.
• Always disclose to your doctor/pharmacist for interaction checks.

Practical “Try It” Checklist

• Identify the itch cause (dermatologic, neuropathic, systemic) and treat underlying issues first.
• Select simple, tested topical product → patch test → trial 2–4 weeks alongside standard care → reassess.
• For oral: Clinician-guided plan with monitoring and stop rules. Avoid driving after THC doses.
• Track symptoms (itch scale, sleep impact, quality of life) and side effects.
• Stop and seek care for worsening skin issues, infection signs, or severe reactions.

Evidence Summary: Reviews (e.g., Trends Pharmacol Sci 2019, Clin Cosmet Investig Dermatol 2020) and recent meta-analyses support adjunctive use, especially topicals for pruritus. No major dermatology guidelines list them as first-line due to evidence gaps, but they are increasingly considered for refractory cases.

Additional Suggestions for Completeness:

• Combine with non-pharmacologic approaches: Wet-wrap therapy (for severe eczema), behavioral itch-scratch interruption techniques, or stress management (itch can worsen with anxiety).
• For sensitive skin: Look for hypoallergenic bases or ceramide-rich formulations paired with cannabinoids.
• Monitor long-term: Re-evaluate every 1–3 months; rotate or taper if effective to minimize any tolerance.
• Emerging: Nano-formulated or liposomal CBD for better penetration; more research expected post-2026 regulatory shifts.

Consult a dermatologist or clinician experienced in medical cannabis before starting, especially for chronic conditions. This is not medical advice—individual responses vary.

In addition:

Cannabinoids show promise as adjunctive options for several other dermatological conditions beyond pruritus, primarily through anti-inflammatory, antioxidant, antimicrobial, sebostatic (oil-regulating), wound-healing, and antiproliferative effects via the skin's endocannabinoid system (CB1/CB2 receptors, TRP channels, PPARs).

Evidence is strongest for symptom management (e.g., inflammation, pain, itch) rather than disease modification or cure. Most data come from preclinical studies, small clinical trials, case series, and 2025 systematic reviews/meta-analyses. High-quality large RCTs are still limited, so they are not first-line treatments.

Key Conditions with Supporting Evidence

• Atopic Dermatitis (Eczema): Topical CBD/CBG or PEA-containing preparations reduce itch, improve hydration, and calm inflammation. A 2025 observational study with CBD/CBG ointment showed lesion remission, better skin barrier, and quality-of-life gains. Often used adjunctively with moisturizers and standard topicals.
• Psoriasis (including scalp psoriasis): Cannabinoids may inhibit keratinocyte hyperproliferation and reduce inflammation/scaling. Small studies and reviews note itch relief and modest plaque improvement with topicals; anti-inflammatory effects are more consistent than full clearance. Nano-formulated CBD enhances penetration.
• Acne: CBD has sebostatic, anti-inflammatory, and antibacterial properties (targets C. acnes). It reduces sebum production and inflammation in sebocytes. Early clinical data support topical use for milder cases; promising but needs more trials.
• Seborrheic Dermatitis and Allergic Contact Dermatitis: Anti-inflammatory and soothing effects reported in reviews; may help with redness, flaking, and immune modulation.
• Rosacea: Preclinical (mouse model) data show CBD reduces erythema, epidermal thickness, and inflammation (via MAPK pathway inhibition). Potential as adjunct to metronidazole.
• Wound Healing and Ulcers (including in systemic sclerosis/scleroderma): Topical CBD promotes healing, reduces pain, and improves quality of life. A randomized trial in scleroderma digital ulcers showed ~72% complete healing (vs. 30% control) with better pain relief and sleep. Also studied in epidermolysis bullosa, pyoderma gangrenosum, and leg ulcers.
• Other Inflammatory/Autoimmune Conditions:
  • Hidradenitis suppurativa, dermatomyositis, cutaneous lupus — preclinical/early signals for inflammation control.
  • Fibrotic diseases (e.g., scleroderma) — potential anti-fibrotic effects.
• Hair and Scalp Disorders: Emerging data for androgenetic alopecia (follicular regeneration) and scalp psoriasis.
• Skin Cancer and Pigmentation: Preclinical antiproliferative/antioxidant effects in melanoma, squamous cell carcinoma, etc. Also studied for melasma/vitiligo. Not a replacement for standard therapies; investigational.

2025 Meta-Analysis Note: Cannabinoids showed statistically significant itch reduction across dermatologic uses, but broader skin outcomes (e.g., lesion clearance) had less consistent or modest benefits overall.

Practical Integration (Building on Prior Itch Guidance)

• Topicals remain preferred — 1–5% CBD creams/ointments, PEA, or nano-formulated products (better penetration). Apply 1–2x daily; patch test; fragrance-free.
• Use as add-on to proven therapies (e.g., topical steroids for eczema/psoriasis, benzoyl peroxide/retinoids for acne, wound care protocols).
• Oral/medical cannabis — Limited role, mainly for severe systemic symptoms under supervision.
• What not to expect — Dramatic rash clearance as monotherapy. Best for symptom relief and supportive care.

Safety and Considerations

Similar to itch section: Topicals are well-tolerated (mild irritation possible). Monitor for interactions with orals. Quality products are essential. Consult a dermatologist — especially for complex conditions like scleroderma, psoriasis, or wounds.

Bottom line: Cannabinoids (especially topical CBD) are an exciting adjunctive tool in dermatology for inflammatory, itchy, and wound-related issues, with growing 2024–2025 evidence. They fit best in multimodal plans when standard options are insufficient. Research is active, with nano-formulations and more trials expected to clarify roles. This is not medical advice—individual results vary, and professional guidance is recommended.